Development of methods for the bioanalysis of RRx-001 and metabolites.
about
NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.
P2860
Development of methods for the bioanalysis of RRx-001 and metabolites.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Development of methods for the bioanalysis of RRx-001 and metabolites.
@ast
Development of methods for the bioanalysis of RRx-001 and metabolites.
@en
type
label
Development of methods for the bioanalysis of RRx-001 and metabolites.
@ast
Development of methods for the bioanalysis of RRx-001 and metabolites.
@en
prefLabel
Development of methods for the bioanalysis of RRx-001 and metabolites.
@ast
Development of methods for the bioanalysis of RRx-001 and metabolites.
@en
P2093
P2860
P356
P1433
P1476
Development of methods for the bioanalysis of RRx-001 and metabolites
@en
P2093
Bryan Oronsky
Michael Taylor
Mike Alexander
Rebecca Cosford
Rebecca Hadar
Thomas Fleischmann
Vance Cooper
William L Fitch
P2860
P304
P356
10.4155/BIO.13.331
P577
2014-04-01T00:00:00Z